TY - JOUR
T1 - Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization
AU - Fan, Katherine Y.
AU - Wild, Aaron T.
AU - Halappa, Vivek G.
AU - Kumar, Rachit
AU - Ellsworth, Susannah
AU - Ziegler, Mark
AU - Garg, Tanu
AU - Rosati, Lauren M.
AU - Su, Zheng
AU - Hacker-Prietz, Amy
AU - Pawlik, Timothy M.
AU - Cosgrove, David
AU - Hong, Kelvin K.
AU - Kamel, Ihab R.
AU - Geschwind, Jean-Francois Francois
AU - Herman, Joseph
N1 - Publisher Copyright:
© 2016
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Objective Yttrium-90 (Y-90) radioembolization is an emerging treatment option for unresectable neuroendocrine liver metastases (NELM). However, the data regarding this treatment are currently limited. This study evaluates the efficacy and tolerability of Y-90 radioembolization and identifies prognostic factors for radiographic response and survival. Methods and materials Thirty-eight patients underwent Y-90 radioembolization for NELM at our institution between April 2004 and February 2012. Patients were assessed radiographically (RECIST criteria, enhancement), serologically, and clinically at 1 month, and then at every 3 months after treatment for tumor response, toxicity, and survival outcomes. Results Median length of follow-up was 17.0 months (IQR, 9.0–37.0). Median survival was 29.2 months. Three patients (9%) had a radiographic complete response to treatment, 6 (17%) had a partial response, 21 (60%) had stable disease, and 5 (14%) developed progressive disease. Two factors were significantly associated with a good radiographic response (complete/partial response): islet cell histological subtype (p = 0.043) and hepatic tumor burden ≥ 33% (p = 0.031). Multivariate analysis revealed that patients requiring multiple Y-90 treatments (HR 2.9, p = 0.035) and patients who had previously failed systemic therapy with octreotide/chemotherapy (HR 4.4, p = 0.012) had worse survival. Grade 3 serologic toxicity was observed in 2 patients (5%; hyperbilirubinemia, elevated alkaline phosphatase) after treatment. Grade 3 non-serologic toxicities included abdominal pain (11%), fatigue (11%), nausea/vomiting (5%), ascites (5%), dyspnea (3%), diarrhea (3%), and peripheral edema (3%). No grade 4 or 5 toxicity was reported. Conclusions Y-90 radioembolization is a promising treatment option for inoperable NELM and is associated with low rates of grade ≥ 3 toxicity.
AB - Objective Yttrium-90 (Y-90) radioembolization is an emerging treatment option for unresectable neuroendocrine liver metastases (NELM). However, the data regarding this treatment are currently limited. This study evaluates the efficacy and tolerability of Y-90 radioembolization and identifies prognostic factors for radiographic response and survival. Methods and materials Thirty-eight patients underwent Y-90 radioembolization for NELM at our institution between April 2004 and February 2012. Patients were assessed radiographically (RECIST criteria, enhancement), serologically, and clinically at 1 month, and then at every 3 months after treatment for tumor response, toxicity, and survival outcomes. Results Median length of follow-up was 17.0 months (IQR, 9.0–37.0). Median survival was 29.2 months. Three patients (9%) had a radiographic complete response to treatment, 6 (17%) had a partial response, 21 (60%) had stable disease, and 5 (14%) developed progressive disease. Two factors were significantly associated with a good radiographic response (complete/partial response): islet cell histological subtype (p = 0.043) and hepatic tumor burden ≥ 33% (p = 0.031). Multivariate analysis revealed that patients requiring multiple Y-90 treatments (HR 2.9, p = 0.035) and patients who had previously failed systemic therapy with octreotide/chemotherapy (HR 4.4, p = 0.012) had worse survival. Grade 3 serologic toxicity was observed in 2 patients (5%; hyperbilirubinemia, elevated alkaline phosphatase) after treatment. Grade 3 non-serologic toxicities included abdominal pain (11%), fatigue (11%), nausea/vomiting (5%), ascites (5%), dyspnea (3%), diarrhea (3%), and peripheral edema (3%). No grade 4 or 5 toxicity was reported. Conclusions Y-90 radioembolization is a promising treatment option for inoperable NELM and is associated with low rates of grade ≥ 3 toxicity.
KW - Liver metastasis
KW - Microsphere
KW - Neuroendocrine tumor
KW - Radioembolization
KW - Unresectable
KW - Yttrium-90
UR - http://www.scopus.com/inward/record.url?scp=84982105633&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84982105633&partnerID=8YFLogxK
U2 - 10.1016/j.cct.2016.08.001
DO - 10.1016/j.cct.2016.08.001
M3 - Article
C2 - 27520932
AN - SCOPUS:84982105633
SN - 1551-7144
VL - 50
SP - 143
EP - 149
JO - Contemporary Clinical Trials
JF - Contemporary Clinical Trials
ER -